相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors
Chara Stavraka et al.
CLINICAL COLORECTAL CANCER (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
Daisaku Kamiimabeppu et al.
ONCOLOGY LETTERS (2021)
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
Ana Fernandez Montes et al.
SCIENTIFIC REPORTS (2021)
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
T. Yoshino et al.
ANNALS OF ONCOLOGY (2020)
Colorectal cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
Jean-Baptiste Bachet et al.
ESMO OPEN (2020)
Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study
Yohei Nose et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
Josep Tabernero et al.
ESMO OPEN (2020)
Real world aspects of palliative trifluridine plus tiperacil (TAS-102) in refractory metastatic colorectal cancer
Mikael Wallander et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
Eric Van Cutsem et al.
EUROPEAN JOURNAL OF CANCER (2018)
Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support
G. H. Lyman et al.
ANNALS OF ONCOLOGY (2018)
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
Julian Walter Holch et al.
EUROPEAN JOURNAL OF CANCER (2017)
Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer
Julia Quidde et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
Alessandro Passardi et al.
ONCOTARGET (2016)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
Alessandro Passardi et al.
PLOS ONE (2015)
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials
G. H. Lyman et al.
ANNALS OF ONCOLOGY (2013)
分享论文
